Unlocking the Future of the Neutropenia Biologic Drug Treatment Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Analyzing the Growth Rate of the Neutropenia Biologic Drug Treatment Market: What’s the Expected CAGR for the Next Decade?
The market size of biologic drugs for treating neutropenia has seen robust growth in the past few years. It is projected to further expand from $13.22 billion in 2024 to $14.08 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.5%. The expansion in the historic period can be attributed to factors including market accessibility and reimbursement, patient advocacy and awareness, physician education and training, biologic drug development and successful clinical trials.
The market size for biologic drug treatment for neutropenia is anticipated to experience robust growth in the forthcoming years. By 2029, it’s predicted to expand to a valuation of $18.1 billion, with a compound annual growth rate (CAGR) of 6.5%. This projected growth during the forecast period is credited to factors such as healthcare cost management, the development of patient-focused care models, combined therapy advancements, regulatory revisions and approvals as well as personalized medicine strategies. Upcoming trends include increased global market access, enhancements in manufacturing methodologies, streamlined treatment protocols, the adoption of biosimilars, and the creation of long-lasting formulations.
What Are the Primary Drivers Supporting the Growth of the Neutropenia Biologic Drug Treatment Market?
The increasing number of cancer cases worldwide is expected to fuel the demand for neutropenia biologic drugs in the market. The rise in cancer diagnoses and the higher percentage of people choosing chemotherapy has led to an uptick in neutropenia sufferers. For example, in January 2022, the American Cancer Society predicted that there would be 1.9 million new cancer cases and approximately 609,360 cancer-related deaths in the US, equating to nearly 1,670 deaths every day. The four most prevalent forms of cancer globally include lung, prostate, bowel and female breast cancer, constituting 43% of all new cancer diagnoses. As such, the global upsurge in cancer cases is foreseen to stimulate the demand in the neutropenia biologic drug treatment market in the upcoming years.
Explore Comprehensive Insights Into The Global Neutropenia Biologic Drug Treatment Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp
What Are the Leading Organizations Impacting the Neutropenia Biologic Drug Treatment Market’s Growth?
Major companies operating in the neutropenia biologic drug treatment market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Celgene Corporation, Biogen Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Gilead Sciences Inc., Daiichi Sankyo Company, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.
How Are the Latest Trends Influencing the Growth of the Neutropenia Biologic Drug Treatment Market?
Significant pharmaceutical companies in the neutropenia biologic drug treatment sector are focusing on the creation of biosimilars as a more economical substitute to existing biologics. Biosimilars are essentially biologic drugs engineered to be almost identical to a pre-approved reference biologic, with no substantial differences in either safety or effectiveness. For instance, Amneal Pharmaceuticals, an American-based pharmaceutical firm, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta in May 2023. This product is targeted at treating and preventing febrile neutropenia in patients receiving chemotherapy. Fylnetra attaches to certain receptors on hematopoietic cells, promoting the expansion and differentiation of neutrophil precursors in the bone marrow. Consequently, this action elevates the production of neutrophils which are vital for warding off infections, especially in patients subjected to myelosuppressive chemotherapy. This aids in reducing the occurrence of febrile neutropenia related to cancer treatments.
Secure Your Global Neutropenia Biologic Drug Treatment Market Report Now for Fast and Efficient Delivery!
Which Industry Segments Are Leading the Development and Expansion of the Neutropenia Biologic Drug Treatment Market?
The neutropenia biologic drug treatment market covered in this report is segmented –
1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim
2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Filgrastim: Brand Name Examples: Neupogen, Indications And Usage
2) By Pegfilgrastim: Brand Name Examples: Neulasta, Indications And Usage
3) By Lenograstim: Brand Name Examples: Granocyte, Indications And Usage
4) By Lipegfilgrastim: Brand Name Examples: Lonquex, Indications And Usage
5) By Sargramostim: Brand Name Examples: Leukine, Indications And Usage
What Regions Are Leading the Charge in the Neutropenia Biologic Drug Treatment Market?
The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
What Does the Definition of the Neutropenia Biologic Drug Treatment Market Include?
Neutropenia biologic drug treatment refers to drugs that are used to reduce fevers or potential infections as well as activate the bone marrow and boost neutrophil production. A lack of neutrophils, a particular type of white blood cell, causes neutropenia.
Browse Through More Similar Reports By The Business Research Company:
Rapid Microbiology Testing Kits Global Market Report 2024
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market
Orthopedic Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/orthopedic-devices-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
